IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.87 USD
-3.73 (-0.78%)
Updated May 6, 2024 04:00 PM ET
After-Market: $476.63 -0.24 (-0.05%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth B Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IDXX 476.87 -3.73(-0.78%)
Will IDXX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IDXX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IDXX
IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed
Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics
IDXX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Idexx Laboratories (IDXX) Tops Q1 Earnings Estimates
Bruker's (BRKR) Balanced Segmental Growth, Innovation Aid
Philips (PHG) Receives FDA Warning Letter Regarding CT Systems
Other News for IDXX
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Idexx Laboratories (IDXX) and ImmunityBio (IBRX)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Owens & Minor (OMI), Idexx Laboratories (IDXX) and CytomX Therapeutics (CTMX)
GLOBAL BRIEFING: China's service sector continues to expand in April
Goldman’s top 50 Strong Balance Sheet stocks
Baron Asset Fund Q1 2024 Shareholder Letter